<img src="https://sb.scorecardresearch.com/p?c1=2&amp;c2=123456&amp;cs_ucfr=1&amp;cv=2.0&amp;cj=1">

Coronavirus | Zydus Cadila gets DCGI nod to initiate Phase-3 clinical trials for COVID-19 vaccine

Vaccine ZyCoV-D was found to be safe, well-tolerated and immunogenic in phase I and II clinical trials

January 03, 2021 04:31 pm | Updated 08:08 pm IST - New Delhi

A shot of the vaccine developed by Zydus Cadila for coronavirus. File

A shot of the vaccine developed by Zydus Cadila for coronavirus. File

Drug firm Zydus Cadila on Sunday said it has received DCGI approval to initiate Phase III clinical trials of its COVID-19 vaccine ZyCoV-D.

The company will now be initiating Phase III clinical trial in around 30,000 volunteers, Zydus Cadila said in a statement.

ZyCoV-D was found to be safe, well-tolerated and immunogenic in phase I and II clinical trials, it added.

The phase II study of ZyCoV-D had been conducted in over 1,000 healthy adult volunteers as part of the adaptive Phase I/II dose-escalation, multi-centric, randomised, double-blind placebo-controlled study, the drug firm said.

The trial has reviewed by an independent data safety monitoring board (DSMB) and reports were submitted to the Central Drugs Standard Control Organisation (CDSCO) regularly for the update on safety outcome.

"We are reaching a critical milestone in our vaccine development programme and towards our goal of helping people fight the pandemic with an indigenously discovered, safe and efficacious vaccine," Zydus Group Chairman Pankaj R Patel said.

The launch of the Phase 3 trial will determine the efficacy of the company's vaccine in preventing COVID-19, which continues to pose a major threat world over, he added.

The Drug Controller General of India (DCGI) on Sunday granted emergency approval to Serum Institute and Bharat Biotech for their respective vaccines.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.